Weekly XXXX -Based Concurrent Chemoradiotherapy for Treatment of Locally Advanced @entity135 : a Single Institution Study.

@entity1 @entity135 @entity697 @entity137 @entity5 @entity900
BACKGROUND: The organ preservation approach of choice for the treatment of locally advanced @entity135 is concurrent chemoradiation with three weekly high doses of @entity900 . Although this is an efficacious treatment policy, it has high @entity697 , which lead to frequent treatment breaks and increased overall treatment time. Hence, the current study was undertaken to evaluate the efficacy of concurrent chemoradiation using 40 mg/m2 weekly @entity900 . MATERIALS AND METHODS: This is a single institutional retrospective study including the data of 266 locally advanced @entity135 @entity1 who were treated with concurrent chemoradiation using 40 mg/m2 weekly @entity900 from January 2012 to January 2014. A p-value of < 0.05 was taken to be significant statistically for all purposes in the study. RESULTS: The mean age of the study @entity1 was 48.8 years. Some 36.1% of the @entity1 had oral cavity primary @entity5 . The mean overall treatment time was 57.2 days. With a mean follow up of 15.2 months for all study @entity1 and 17.5 months for survivors, 3 year local control, locoregional control and disease free survival were seen in 62.8%, 42.8% and 42.1% of the study @entity1 . Primary @entity5 site, nodal stage of disease, AJCC stage of the disease and number of cycles of weekly @entity900 demonstrated statistically significant correlations with 3 year local control, locoregional control and disease free survival. CONCLUSIONS: Concurrent chemoradiotherapy with moderate dose weekly @entity900 is an efficacious treatment regime for locally advanced @entity135 with tolerable @entity137 which can be used in developing countries with limited resources.
